 
  
        
        
        Back to top        
        
        
  
    
      
  
  
    
      
      
  
    
                        
          
  
    
      
  
    
          
  
    
      
      
  
    
        
                              
          
  
    
      
            
      
  
    
        
                                                                                                                                                                              
  
  
    
                        
          
  
    
      
            
      
  
    
        
                                                                                                                                                                                              
  
  
    
                        
            
  
  
  
      
              
    
              
    
    
  
  
        
                                                                                                                                                                                              
  
  
    
                        
          
  
    
      
      
        
      
    
  
  
    
        
                              
          
        
                                                                                                                                                                              
  
  
    
                        
          
  
    
      
            
      
  
        
                              
          
        
                                                                                                                                                                              
  
  
    
                        
           
        
        
              
        
  
  
      
      
        
            
      
      
      
    
  
        
                                                                                                                                                                                              
  
  
    
                        
          
  
    
      
            
      
  
        
                                                                                                                                                                                              
  
   
  
      
    
      Video1 minute watch
  
  
    
Is ASDAS <2.1 clinically meaningful for patients with axSpA?
EU-DA-2400662
  Watch Prof Robert Landewé discuss the importance of using ASDAS <2.1 as a treatment target for patients with axSpA.
Other videos you might like
Recommended videos
You can read more videos that might interest you.
Want to see more videos?
Can’t find the answer you’re looking for? See all the Resources we have.
 
 
